Log in | Register

Bausch + Lomb Appoints Dr. Calvin W. Roberts as Chief Medical Officer(2)

For the latest pharmaceutical news and updates - Sign up now!
Loading...

Bausch + Lomb has announced the appointment of Calvin W. Roberts, M.D. to the newly created position of Chief Medical Officer (CMO). Dr. Roberts will serve as a member of the Executive Leadership Team and coordinate the company's global D&R efforts across the Vision Care, Pharmaceuticals and Surgical business units for greater leverage and outcomes.

Dr. Roberts brings a unique combination of academic, clinical and product development experience to the new Bausch + Lomb CMO role. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing and producing over-the-counter products for vision care, prescription ocular therapeutics and innovative treatment regimens. Dr. Roberts is considered to be the "father" of ophthalmic non-steroidals; he has published 50 peer-reviewed articles.

"We are extremely pleased with the addition of Dr. Calvin Roberts to the Bausch + Lomb leadership team in this critical new role as chief medical officer," said Brent Saunders, chief executive officer of Bausch + Lomb. "As a renowned expert in ophthalmology and the development of eye health products, Cal is uniquely qualified to help us further strengthen product innovation, benefiting our customers and their patients around the world."

Dr. Roberts is a member of the board of directors at Alimera Sciences, a biopharmaceutical company he co-founded in 2003. Dr. Roberts is a clinical professor of ophthalmology at Weill Medical College of Cornell University. Dr. Roberts holds patents on the wide-field specular microscope, used for corneal endothelial studies, and is the developer of instruments for cataract surgery. As a consultant to ophthalmic pharmaceutical companies, including Allergan Pharmaceuticals, Johnson & Johnson and Novartis, Dr. Roberts has helped lead the development and marketing efforts for several new therapeutics.

A graduate of Princeton University and the College of Physicians and Surgeons of Columbia University, Dr. Roberts completed his internship and ophthalmology residency at Columbia Presbyterian Hospital in New York. Dr. Roberts also completed cornea fellowships at Massachusetts Eye and Ear Infirmary and the Schepens Eye Research Institute in Boston.

"I look forward to bringing the perspective of clinical optometrists and ophthalmologists to the development of new, innovative products to benefit our patients," said Dr. Calvin Roberts. "Bausch + Lomb has a history of great science and great scientists, and working together we can best serve the needs of our customers and patients."

 

Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Lung Cancer Drug Treats Rare Lymphoma Tumors

Lung Cancer Drug Treats Rare Lymphoma Tumors

May 17 | Video

A new study found Xalkori effective in treating anaplastic lymphoma among children, an encouraging development for gene-targeted therapy.

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter